Amoebiasis caused by the protozoan parasite Entamoeba histolytica remains a major public health 22 hazard, as being the second cause of death among parasitic infections. Although currently 23 prescribed drugs have shown to be effective in the treatment of amoebiasis, side effects and 24 emergence of parasites resistance prompted the search for novel drug to control this disease. In 25 this regard, the Medicines for Malaria Venture (MMV) Pathogen Box library of selected 26 compounds was screened to identify anti-Entamoeba histolytica agents using the resazurin based 27 fluorescence assay. Overall, the results revealed three novel anti-Entamoeba histolytica scaffolds 28 with low micromolar activity including MMV675968 (IC 50 = 2.10 µM), MMV688179 (IC 50 = 2.38 29 µM) and MMV688844 (IC 50 = 5.63 µM). Structure-Activity-Relationship (SAR) studies led to 30 identification of two analogs ~100 fold more potent and selective than the original hit compound 31 1 (MMV675968): 1k (IC 50 = 0.043 µM) and 1l (IC 50 = 0.055 µM). Predictive analysis using 32 Maestro 11.6 suggested that these hit compounds possess acceptable physicochemical and 33 metabolism properties. These lead compounds are therefore good starting points for lead 34 optimization studies towards identification of drug candidate against amoebiasis. 35 36 37 38 39 40 3 41 Author Summary 42
Assay validation through Z-factor determination 143 To validate our resazurin reduction assay, the statistical effect size (Z-factor) was calculated. In a 144 96 wells plate format, E. histolytica (2×10 4 cells/mL) was cultured in Eagle's minimum essential 145 medium (EMEM) (Sigma, Germany) supplemented with 10% albumin bovine serum (ABS) and 146 1% penicillin-streptomycin solution for 48 h at 37˚C, 5% CO 2 . After 48h incubation, 10 μL 147 resazurin at 0.01% (wt/vol) were added in each well and incubated in the dark for 30 min at 37˚C.
148
Plates were scanned using a Tecan Infinite M200 fluorescence multi-well plate reader (Männedorf, 149 Switzerland) with excitation and emission at 530 and 590 nm respectively. More than 30 replicate 150 of the negative control (Parasite-free inhibitor), positive control (1mg/mL metronidazole in 100% 151 DMSO) and the blank (medium-free parasite) were prepared. The assay was performed twice and 152 the data were used to calculate the Z-factor using the formula: 153 Where σp and σn are the standard deviations of the positive and negative controls respectively, and 154 μp and μn are the corresponding mean values. A Z-factor between 0.5 and 1.0 indicates an excellent 155 assay and statistically reliable separation between the positive and negative controls. 
206
Z-factor value for assay validation 207 The quality of the screen was evaluated using the Z-factor based on the percent inhibition against 208 E. histolytica between the 1.0% DMSO and 1mg/mL metronidazole-treated parasites taken as the here for the first time as having amoebicidal activity (Fig 4; Table 1 ). Given their lipophilicity in In an attempt to confirm their potency upon retesting, and identify more potent and selective anti-255 amoebic hits, compounds 1, 2 and 3 were resynthesized and fresh DMSO solutions were prepared 256 from solid samples before testing against E. histolytica as described above.
257 Surprisingly upon testing, the activity was not confirmed for compounds 2 and 3 since a complete 258 loss of inhibitory effect against E. histolytica was observed at concentrations below 25µM. Further 259 investigation through available structural analogs of these 2 hits did not show any inhibition 260 against E. histolytica while their cytotoxicity values were significant (see Supporting Information).
261
These results suggest that primary activity observed for compounds 2 and 3 might be due to their 262 cytotoxicity or to degradation of the compound under the storage condition of the Pathogen Box. true 'hit' molecule as a compound which has the desired activity in a compound screen and whose 267 activity is confirmed upon retesting. This is as true as the success to identify candidate molecules 268 for clinical development depends upon the stability of the potency over time.
269
Upon retest, compound 1 showed a 3.6-fold decrease in potency (IC 50 from 2.100 to 7.495 µM) as 270 well as the selectivity against Vero cell line (SI 5.5). Although slightly disappointed by this loss 271 of potency, this activity level confirmed to be below 10 µM prompted us to test structural analogs 272 of compound 1. This has allowed to establish rudimentary structure-activity-relationship (SAR) 273 and to identify two analogs ~100 fold more potent than the parent hit compound.
274

Structure activity relationship 275
Twenty-three analogs of compound 1 were available as solids from MMV as part of the Pathogen
276
Box initiative and tested against E. histolytica as an opportunistic approach (see Supporting
277
Information for data on all compounds). The key results allowing to establish very preliminary 278 SAR around compound 1 are summarized in Table 2 below.
279
Compounds 1a-1d show different substitution pattern around the phenyl moiety of the hit 280 compound 1 while keeping unchanged the 5-chloro-2,4-diaminoquinazoline core. Among these 281 structural analogs, 1b was found to be the most potent (IC 50 = 0.123 µM). This 61-fold increase in 282 potency vs. the hit compound 1 results from incorporation of an ortho-methoxy as the only 283 substituent of the phenyl moiety. Replacement of this methoxy with a methyl group did not result 284 in significant activity improvement (compound 1d). 285 The additional analogs depicted in Table 2 deal with modifications of the core moiety. Removal dm -3 is the concentration of the solute in a saturated solution that is in equilibrium with the crystalline solid (recommended values: -6.5 -0.5); QPlogHERG: Predicted IC 50 295 value for blockage of hERG K+ channels (recommended values: concern below -5); QPPCaco: Predicted apparent Caco-2 cell permeability in nm/sec. Caco2 cells are a model 296 for the gut-blood barrier (Range: ˂25 poor and >500 great); QPlogBB: Predicted brain/blood partition coefficient (recommended values: -3.0 -1.2); QPPMDCK: Predicted 297 apparent MDCK cell permeability in nm/sec. MDCK cells are considered to be a good mimic for the blood brain barrier (Range: ˂25 poor and >500 great); QPlogKhsa:
298
Prediction of binding to human serum albumin (range: -1.5 -1.5); HOA: Human Oral Absorption Predicted qualitative human oral absorption: 1, 2, or 3 for low, medium, or 299 high respectively. LogP: lipophilicity (recommended values: LogP <5).
300
Interestingly, 2,4-diaminopyrimidine as core moiety led to a dramatic improvement in potency 301 with compounds 1k and 1l showing 3-and 93-fold activity increase respectively when compared 302 to their 5-chloro-2,4-diaminoquinazoline analogs 1b and 1c. Overall, screening of the available 303 analogs of the hit compound 1 has allowed to improve the in vitro potency against E. histolytica 304 by 147-fold.
305
1l and 1k constitute promising starting points. However, it would be key to assess the scope for 306 modifications around the phenyl moiety and to determine which functionalities could be tolerated.
